David Lamond

Filings by David Lamond span 2 companies, the busiest being IRulya Therapeutics Inc. and Applied Molecular Transport Inc. Over a trading history stretching from 19 May 2022 to 12 December 2023, the count stands at 7 filings.

Every open-market trade on record is a purchase: 6 purchases worth €307k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. 2023 to date brings 5 purchases and no sales.

Half of the purchases are above €33k and half below. Clusters matter here: 3 out of 6 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 14 December 2023 came the latest disclosure, an open-market purchase for €279 in IRulya Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.